drugset / Trial / NCT00734734

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

NCT00734734

Phase 2 Completed 64 enrolled Novartis Vaccines
NaSingle-groupOpen-labelPrevention

Summary

Trial for annual approval of interpandemic influenza vaccines

Timeline

Start
2008-06
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Quadrivalent influenza vaccine Vaccine Intramuscular

Indications

No indication recorded.